Advanced Ovarian Cancer Pipeline Analysis | Insights into Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook | Key Players – ImmunoGen, Celsion

 Breaking News
  • No posts were found

Advanced Ovarian Cancer Pipeline Analysis | Insights into Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook | Key Players – ImmunoGen, Celsion

September 15
18:16 2022
Advanced Ovarian Cancer Pipeline Analysis | Insights into Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook | Key Players - ImmunoGen, Celsion
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, nearly 50+ key pharma and biotech companies are working on 50+ pipeline drugs in the Advanced Ovarian Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Advanced Ovarian Cancer Pipeline Insight, 2022” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Ovarian Cancer Market. 

The Advanced Ovarian Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Advanced Ovarian Cancer Pipeline Analysis

Advanced Ovarian Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Ovarian Cancer with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Advanced Ovarian Cancer Treatment.

  • Advanced Ovarian Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Advanced Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Advanced Ovarian Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Advanced Ovarian Cancer: Overview

Chemotherapy, surgery, and targeted cancer drugs are all treatments for Advanced Ovarian Cancer. Some women may have radiotherapy. Targeted cancer drugs can help the body control cancer cell growth. Occasionally doctors suggest radiotherapy for Advanced Ovarian Cancer. Radiotherapy can shrink tumors and reduce symptoms.

Key Developments in the Advanced Ovarian Cancer Therapeutics Market

• On September 15, 2022, Celsion Corporation (NASDAQ: CLSN) announced that its Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer had completed enrollment. GEN-1 is Celsion’s IL-12 gene-mediated immunotherapy.

• On September 11, 2022, Clovis Oncology, Inc. (NASDAQ: CLVS), announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA (GOG-3020/ENGOT-ov45) trial (ATHENA-MONO) at the European Society of Medical Oncology (ESMO) Congress 2022 in Paris. The data demonstrated that Rubraca as a first-line maintenance treatment enhanced progression-free survival (PFS) across disease risk subgroups.

DelveInsight’s Report covers around 50+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Request for Sample PDF Report –

Advanced Ovarian Cancer Therapeutics Landscape

There are approx. 50+ key companies which are developing therapies for Advanced Ovarian Cancer. ImmunoGen has its Advanced Ovarian Cancer drug candidates in the most advanced stage (phase III) of clinical development.

Key companies in the Advanced Ovarian Cancer Therapeutic Market include:

ImmunoGen, Celsion Corporation,  Clovis Oncology, OncoQuest, Lee’s Pharmaceutical, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Boehringer Ingelheim, Impact Therapeutics, Inc., Glycotope, Puma Biotechnology, Inc., MaxCyte, Inc., Bayer, Xennials Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc, and others.

Advanced Ovarian Cancer Emerging Drugs

• Mirvetuximab soravtansine (IMGN853 (ImmunoGen)

• Oregovomab (OncoQuest)

And many more 

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Advanced Ovarian Cancer Current Treatment Patterns

4. Advanced Ovarian Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Advanced Ovarian Cancer Late Stage Products (Phase-III)

7. Advanced Ovarian Cancer Mid-Stage Products (Phase-II)

8. Advanced Ovarian Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Advanced Ovarian Cancer Discontinued Products

13. Advanced Ovarian Cancer Product Profiles

14. Key Companies in the Advanced Ovarian Cancer Market

15. Key Products in the Advanced Ovarian Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Advanced Ovarian Cancer Unmet Needs

18. Advanced Ovarian Cancer Future Perspectives

19. Advanced Ovarian Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Platinum-Resistant Relapsed Ovarian Cancer Market
“Platinum-Resistant Relapsed Ovarian Cancer Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Platinum-Resistant Relapsed Ovarian Cancer Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles